Inotiv Net Income Over Time
| NOTV Stock | USD 0.43 0.05 10.50% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Inotiv Performance and Inotiv Correlation. What growth prospects exist in Life Sciences Tools & Services sector? Can Inotiv capture new markets? Factors like these will boost the valuation of Inotiv. Anticipated expansion of Inotiv directly elevates investor willingness to pay premium valuations. Valuation analysis balances hard financial data with qualitative growth assessments. While each Inotiv valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Earnings Share (2.11) | Revenue Per Share | Quarterly Revenue Growth 0.059 | Return On Assets | Return On Equity |
The market value of Inotiv Inc is measured differently than its book value, which is the value of Inotiv that is recorded on the company's balance sheet. Investors also form their own opinion of Inotiv's value that differs from its market value or its book value, called intrinsic value, which is Inotiv's true underlying value. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. Because Inotiv's market value can be influenced by many factors that don't directly affect Inotiv's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Inotiv's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Inotiv should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Inotiv's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Inotiv Inc and related stocks such as Rein Therapeutics, Biodesix, and Volitionrx Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RNTX | (21.2 K) | (21.2 K) | (21.2 K) | (21.2 K) | (21.2 K) | (21.2 K) | (21.2 K) | (21.2 K) | (21.2 K) | (21.2 K) | (21.2 K) | (26.2 K) | (27.3 K) | (15.7 K) | (62.9 M) | (56.6 M) | (53.8 M) |
| BDSX | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (30.7 M) | (31.4 M) | (43.2 M) | (65.4 M) | (52.1 M) | (42.9 M) | (38.6 M) | (40.6 M) |
| VNRX | (24.2 K) | (2.6 M) | (4.1 M) | (3.7 M) | (8.2 M) | (9.5 M) | (11.9 M) | (14.8 M) | (18 M) | (16.1 M) | (20.4 M) | (26.8 M) | (30.3 M) | (35.3 M) | (27 M) | (24.3 M) | (23.1 M) |
| BEAT | (12.7 M) | (61.4 M) | (12.2 M) | (7.3 M) | (9.8 M) | 7.4 M | 53.4 M | (16 M) | 42.8 M | (778 K) | (1.3 M) | (4.4 M) | (12.8 M) | (14.6 M) | (19.4 M) | (22.4 M) | (21.2 M) |
| STRR | (13.5 M) | (3.3 M) | (4.9 M) | 264 K | 2.5 M | 21.6 M | 14.3 M | (35.7 M) | 736 K | (4.6 M) | (6.5 M) | (3 M) | (5.3 M) | 2.2 M | (10.4 M) | (12 M) | (11.4 M) |
| CELU | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (211.9 M) | (208.2 M) | (100.1 M) | 14.2 M | (196.3 M) | (57.9 M) | (66.6 M) | (69.9 M) |
| BIAF | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (7.3 M) | (6.3 M) | (8.2 M) | (7.9 M) | (9 M) | (8.1 M) | (8.5 M) |
| KZR | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (8.5 M) | (23.2 M) | (31.5 M) | (39 M) | (54.6 M) | (65.3 M) | (101.9 M) | (83.7 M) | (75.4 M) | (71.6 M) |
| QNTM | (32.8 K) | (32.8 K) | (32.8 K) | (32.8 K) | (32.8 K) | (32.8 K) | (29.6 K) | (2.8 M) | (16.7 M) | (39.1 M) | (31.8 M) | (35.3 M) | (23.6 M) | (17.9 M) | (14.2 M) | (12.8 M) | (13.4 M) |
Inotiv Inc and related stocks such as Rein Therapeutics, Biodesix, and Volitionrx Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Inotiv Inc financial statement analysis. It represents the amount of money remaining after all of Inotiv Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Inotiv Inc | NOTV |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 2701 Kent Avenue, |
| Exchange | NASDAQ Exchange |
USD 0.4296
Additional Tools for Inotiv Stock Analysis
When running Inotiv's price analysis, check to measure Inotiv's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inotiv is operating at the current time. Most of Inotiv's value examination focuses on studying past and present price action to predict the probability of Inotiv's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inotiv's price. Additionally, you may evaluate how the addition of Inotiv to your portfolios can decrease your overall portfolio volatility.